RxDoctor Payments Data

Vince Ha, MD

Nephrology · Corona, CANPI 1568587061

Payments from drug & device makers

$5,620in general payments, 2019–2025

Across 208 payments — averaging $27.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$438
  • Aurinia Pharma U.S., Inc.$424
  • Travere Therapeutics, Inc.$367
  • Akebia Therapeutics Inc$344
  • Calliditas Therapeutics US Inc.$334
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$5,58399%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,620 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$207,716
Medicare patients
364
Services billed
1,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate146$155,340
FarxigaDapagliflozin Propanediol205$151,708
XphozahTenapanor Hcl41$130,584
VelphoroSucroferric Oxyhydroxide26$77,577
AuryxiaFerric Citrate48$51,076
JardianceEmpagliflozin64$40,602
VeltassaPatiromer Calcium Sorbitex30$35,536
Sevelamer Carbonate94$35,435
ProcritEpoetin Alfa30$33,682
DapagliflozinDapagliflozin Propanediol25$23,225
Sevelamer Hcl22$22,436
ZenpepLipase/Protease/Amylase13$18,099
RetacritEpoetin Alfa-Epbx32$16,356
EliquisApixaban13$14,620
Lanthanum Carbonate24$13,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$1,890$307,048351 claims
Fresenius USA Marketing, Inc.Velphoro$113$77,57726 claims
Akebia Therapeutics IncAuryxia$344$51,07648 claims
Boehringer IngelheimJardiance$92$40,60264 claims
ANI Pharmaceuticals, Inc.Valsartan$95$30415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.

Other nephrology in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →